- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00744107
Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease
The Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Safety and Efficacy will be demonstrated by the rate of Target vessel failure (TVF), defined as cardiac death, target vessel myocardial infarction (MI) [Q wave or non-Q wave], or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods within 270 days of the post-stent placement procedure.
Additionally, Major Adverse Cardiac Events (MACE)at 30, 180 and 270 days defined as a composite of all-cause death, myocardial infarction (MI) (Q wave and non-Q wave), emergent bypass surgery, or clinically driven target lesion revascularization (TLR) [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)]will be documented.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bad Soden, Germany, 65812
- Main Taunus Kliniken, Kardiologisches
-
Essen, Germany, 45141
- St. Vincenz Krankenhaus
-
Trier, Germany, 54292
- Krankenhaus der Barmherzigen Brüder
-
-
-
-
-
Jerusalem, Israel, 91120
- Hadassah Hebrew University Medical Center
-
-
-
-
-
Eindhoven, Netherlands, 5623 EJ
- Catharina-ziekenhuis
-
-
-
-
-
Edinburgh, United Kingdom, EH16 4SA
- Royal Infirmary
-
Glasgow, United Kingdom, G81 4HX
- Golden Jubilee Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is ≥ 18 years old;
- Subject is eligible for percutaneous coronary intervention (PCI), stent placement, and emergent coronary artery bypass graft (CABG) surgery;
- Subject has clinical evidence of ischemic heart disease, stable or unstable angina or silent ischemia;
- The subject has a documented left ventricular ejection fraction (LVEF) ≥ 30%;
- The subject or legal representative has been informed of the clinical study and the required follow-up procedures and must provide written informed consent using a form that is reviewed and approved by the Institutional Review Board/Ethics Committee (IRB/EC) for the clinical site;
- Female subjects of childbearing potential must have a negative pregnancy test within 7 days before treatment;
- Subject must agree to comply with the required follow-up procedures (including antiplatelet regimen) to the best of their ability, be geographically available for all study follow-up procedures and visits and not have a known medical condition that precludes completion of the required follow-up visits;
- The lesion is either de novo or restenotic (previously unstented) in nature, located in a native coronary artery AND is ≥ 50% and < 100% stenosed by visual estimate or on-line QCA;
- The target vessel reference diameter ≥ 2.5mm and ≤ 4mm by visual estimate and is appropriate for treatment with available stent diameters of 2.5 mm, to 4.0 mm;
- The lesion length is ≤ 26 mm and able to accommodate placement of a single stent;
- The target lesion is a minimum of 15 mm from any previously placed stent; AND
- The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥ 2
Exclusion Criteria:
- The subject has a known hypersensitivity or contraindication to aspirin, heparin and bivalirudin, ticlopidine and clopidogrel, cobalt, nickel, chromium, molybdenum, or a sensitivity to contrast media, which cannot be adequately pre-medicated;
- A platelet count < 100,000 cells/mm³ or > 700,000 cells/mm³, or a WBC < 3,000 cells/mm³;
- A creatinine level > 2.5 mg/dL within 7 days prior to the index procedure;
- Evidence of an acute myocardial infarction (MI) within 72 hours of the intended treatment (defined as: Q wave (QWMI) or any elevation of creatine kinase myocardial-band (CK-MB) isoenzyme elevated above the Institution's upper limit of normal;
- Any previous PCI (with or without stent) of the target vessel within 30 days prior to the index procedure;
- Previous stent placement anywhere in the target lesion;
- Previous drug eluting stent (DES) deployment anywhere in the target vessel;
- The subject requires staged procedure of any non-target vessel within 30 days post-procedure;
- The subject requires staged procedure of the target vessel within 9 months post-procedure;
- The target lesion requires treatment with a device other than PTCA prior to stent placement (including, but not limited to, cutting balloon, directional coronary atherectomy, excimer laser, rotational atherectomy, thrombectomy, etc.;
- History of a stroke or transient ischemic attack (TIA) within the previous 6 months;
- Active peptic ulcer or upper gastrointestinal (GI) bleeding within the previous 6 months;
- History of bleeding diathesis or coagulopathy or will refuse blood transfusions;
- A known concurrent medical condition resulting in a life expectancy of less than 12 months;
- Any previous or planned treatment of the target vessel with anti-restenotic therapies including, but not limited to brachytherapy;
- The subject is currently participating in another investigational device or drug study and has not completed the primary endpoint(s) follow-up phase of that study at least 30 days prior to enrollment in this trial; or interferes with the current trial endpoints; or the subject has previously been enrolled in the study;
- The subject has a known medical condition that will cause them to be non-compliant with the study protocol or confound the data interpretation;
- The target vessel has evidence of thrombus or other lesions having a > 60% stenosis by visual estimate or on-line QCA;
- Target vessel exhibiting multiple lesions with greater than 60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line QCA;
- The target vessel has evidence (visual or QCA) of excessive tortuosity (two or more 90° bends prior to the target lesion) or is severely calcified; OR
- The target lesion is in an unprotected left main, involves a side branch vessel having a diameter of > 2.0 mm or is at the aorto-ostial location
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Target vessel failure (TVF), defined as cardiac death, target vessel myocardial infarction (MI) [Q wave or non-Q wave], or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods.
Time Frame: 270 days
|
270 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MACE defined as all-cause death, MI, emergent CABG, or clinically driven TLR; TVF; 6 month In-segment %DS, late lumen loss, binary restenosis and In-stent %DS,late lumen loss, binary restenosis, MLD
Time Frame: 30-, 180- and 270-days
|
30-, 180- and 270-days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof. Nicolaus J Reifart, PhD, MD, Main Taunus Kliniken, Kardiologisches
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 59-2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System
-
CID - Carbostent & Implantable DevicesCompletedMyocardial Ischemia | Coronary Stenosis | Coronary Artery Diseases | Coronary Atherosclerotic Disease | Coronary Occlusive DiseasesItaly
-
Ceric SàrlBoston Scientific CorporationCompletedAcute Coronary Syndrome | Stable Angina | Silent Myocardial IschemiaFrance, Spain, Belgium, Switzerland, United Kingdom, Latvia, Finland, Italy, North Macedonia
-
Spanish Society of CardiologyCompletedMyocardial InfarctionSpain, Italy, Netherlands
-
Stryker NeurovascularCompletedIntracranial AtherosclerosisFrance, Germany
-
IHF GmbH - Institut für HerzinfarktforschungRecruiting